Chronic administration of resveratrol prevents morphological changes in prefrontal cortex and hippocampus of aged rats

Synapse

Volumn 70, Issue 5, 2016, Pages 206-217

  Monserrat Hernández Hernández, Elizabeth ^a   Serrano García, Carolina ^a   Antonio Vázquez Roque, Rubén ^a   Díaz, Alfonso ^a   Monroy, Elibeth ^a   Rodríguez Moreno, Antonio ^b   Florán, Benjamin ^c   Flores, Gonzalo ^a  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^c Centro de Investigaciones y Estudios Avanzados IPN   (Mexico)

Author keywords

Aging; Dendritic morphology; Hippocampus; Neuronal plasticity; Nucleus accumbens; Prefrontal cortex; Resveratrol

Indexed keywords

RESVERATROL; ANTIOXIDANT; STILBENE DERIVATIVE;

AGED; AGING; ANIMAL EXPERIMENT; ARTICLE; CELL STRUCTURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DENDRITE; DENDRITIC SPINE; DENTATE GYRUS; DORSAL HIPPOCAMPUS; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; LOCOMOTION; MALE; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; VENTRAL HIPPOCAMPUS; ANIMAL; CYTOLOGY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; DENDRITES; HIPPOCAMPUS; MALE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

EID: 84975690975     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21888     Document Type: Article

References (70)

1. Aoki C, Mahadomrongkul V, Fujisawa S, Habersat R, Shirao T. 2007. Chemical and morphological alterations of spines within the hippocampus and entorhinal cortex precede the onset of Alzheimer's disease pathology in double knock-in mice. J Comp Neurol 505:352-362.
2. Alquicer G, Silva-Gómez AB, Peralta F, Flores G. 2004. Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. Int J Dev Neurosci 22:103-111.
3. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342.
4. Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5:493-506.
5. Burke SN, Barnes CA. 2006. Neural plasticity in the ageing brain. Nat Rev Neurosci 7:30-40.
6. Cuevas E, Limón D, Pérez-Severiano F, Díaz A, Ortega L, Zenteno E, Guevara J. 2009. Antioxidant effects of epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur J Pharmacol 616:122-127.
7. Dal-Pan A, Pifferi F, Marchal J, Picq JL, Aujard F. 2011. RESTRIKAL Consortium. Cognitive performances are selectively enhanced during chronic caloric restriction or resveratrol supplementation in a primate. PLoS One 6:e16581-
8. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G. 2012. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxid Med Cell Longev 386527-
9. Daenen EW, Wolterink G, Van Der Heyden JA, Kruse CG, Van Ree JM. 2003. Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic startle response; implications for an animal model of neurodevelopmental disorders like schizophrenia. Eur Neuropsychopharmacol 13:187-197.
10. de la Lastra CA, Villegas I. 2005. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol Nutr Food Res 49:405-430.
11. Del Arco A, Segovia G, Mora F. 2001. Dopamine release during stress in the prefrontal cortex of the rat decreases with age. Neuroreport 12:4019-4022.
12. Diaz A, Limon D, Chávez R, Zenteno E, Guevara J. 2012. Aβ25-35 injection into the temporal cortex induces chronic inflammation that contributes to neurodegeneration and spatial memory impairment in rats. J Alzheimers Dis 30:505-522.
13. Díaz A, Rojas K, Espinosa B, Chávez R, Zenteno E, Limón D, Guevara J. 2014. Aminoguanidine treatment ameliorates inflammatory responses and memory impairment induced by amyloid-beta 25-35 injection in rats. Neuropeptides 48:153-159.
14. Einstein G, Buranosky R, Crain BJ. 1994. Dendritic pathology of granule cells in Alzheimer's disease is unrelated to neuritic plaques. J Neurosci 14:5077-5088.
15. Ferrer I, Gullotta F. 1990. Down's syndrome and Alzheimer's disease: Dendritic spine counts in the hippocampus. Acta Neuropathol 79:680-685.
16. Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell'aquila C, De Mari M, Ferranini E, Bonifati V, Pacelli C, Cocco T. 2014. Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson's disease. Biochim Biophys Acta 1842:902-915.
17. Flores-Tochihuitl J, Vargas G, Morales-Medina JC, Rivera G, De La Cruz F, Zamudio S, Flores G. 2008. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (1)-S14297. Synapse 62:40-49.
18. Flores G, Barbeau D, Quirion R, Srivastava LK. 1996a. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 16:2020-2026.
19. Flores G, Wood GK, Liang JJ, Quirion R, Srivastava LK. 1996b. Enhanced amphetamine sensitivity and increased expression of dopamineD2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. J Neurosci 16:7366-7375.
20. Flores G, Alquicer G, Silva-Gomez AB, Zaldivar G, Stewart J, Quirion R, Srivastava LK. 2005. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 133:463-470.
21. Flores G, Flores-Gómez GD, Gómez-Villalobos MJ. 2016. Neuronal changes after chronic high blood pressure in animal models and its implication for vascular dementia. Synapse, DOI: 10.1002/syn.21887
22. Fukui M, Yamabe N, Kang KS, Zhu BT. 2010. Growth-stimulatory effect of resveratrol in human cancer cells. Mol Carcinog 49:750-759.
23. Gibb R, Kolb B. 1998. A method for vibratome sectioning of Golgi-Cox stained whole rat brain. J Neurosci Methods 79:1-4.
24. Grill CJ, Sivaprasad U, Cohick WS. 2002. Constitutive expression of IGF-binding protein-3 by mammary epithelial cells alters signaling through Akt and p70S6 kinase. J Mol Endocrinol 29:153-162.
25. Halliwell B. 2007. Biochemistry of oxidative stress. Biochem Soc Trans 35:1147-1150.
26. Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL. 2011. Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 6:e29102-
27. Jang JH, Surh YJ. 2003. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 34:1100-1110.
28. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
29. Jing YH, Chen KH, Kuo PC, Pao CC, Chen JK. 2013. Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment withresveratrol. Neuroendocrinology 98:116-127.
30. Juárez I, González DJ, Mena R, Flores G. 2011. The chronic administration of cerebrolysin induces plastic changes in the prefrontal cortex and dentate gyrus in aged mice. Synapse 65:1128-1135.
31. Kodali M, Parihar VK, Hattiangady B, Mishra V, Shuai B, Shetty AK. 2015. Resveratrol prevents age-related memory and mood dysfunction with increased hippocampal neurogenesis and microvasculature, and reduced glial activation. Sci Rep 5:8075-
32. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH. 2007. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26:3169-3179.
33. Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-Espinosa I, Ferrer I, DeFelipe J. 2009. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex 19:586-592.
34. Knobloch M, Mansuy IM. 2008. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol Neurobiol 37:73-82.
35. Kulkarni SS, Cantó C. 2015. The molecular targets of resveratrol. Biochim Biophys Acta 1852:1114-1123. doi: 10.1016/j.bbadis.2014.10.005.
36. Kwon KJ, Kim HJ, Shin CY, Han SH. 2010. Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein kinase pathways. J Clin Neurol 6:127-137.
37. Lazcano Z, Solis O, Bringas ME, Limón D, Diaz A, Espinosa B, García-Peláez I, Flores G, Guevara J. 2014. Unilateral injection of Aβ25-35 in the hippocampus reduces the number of dendritic spines in hyperglycemic rats. Synapse 69:314-325.
38. Li SY, Wang XB, Kong LY. 2014. Design synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur J Med Chem 71:36-45.
39. Lindsey JD, Duong-Polk KX, Hammond D, Leung CK, Weinreb RN. 2015. Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol. Neurobiol Aging 36:1969-1981.
40. Lopez MS, Dempsey RJ, Vemuganti R. 2015. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int 89:75-82.
41. Ma T, Tan MS, Yu JT, Tan L. 2014. Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int 2014:350516- doi: 10.1155/2014/350516
42. Martinez-Tellez R, Gómez-Villalobos MJ, Flores G. 2005. Alteration in dendritic morphology of cortical neurons in rats with diabetes mellitus induced by streptozotocin. Brain Res 1048:108-115.
43. Mattson MP, Magnus T. 2006. Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278-294.
44. Mizutani K, Ikeda K, Kawai Y, Yamori Y. 2001. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 28:55-59.
45. Moriya J, Chen R, Yamakawa J, Sasaki K, Ishigaki Y, Takahashi T. 2011. Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells. Biol Pharm Bull 34:354-359.
46. O'Donnell E, Vereker E, Lynch MA. 2000. Age-related impairment in LTP is accompanied by enhanced activity of stress-activated protein kinases: analysis of underlying mechanisms. Eur J Neurosci 12:345-352.
47. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates academic, 4th ed. Press, New York: Academic Press.
48. Rahvar M, Nikseresht M, Shafiee SM, Naghibalhossaini F, Rasti M, Panjehshahin MR, Owji AA. 2011. Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain. Neurochem Res 36:761-765.
49. Robinson TE, Kolb B. 1997. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17:8491-8497.
50. Rojas K, Díaz A, Espinosa B, Montaño LF, Dilhuydy H, Geraux F, Joanette Y, Robitaille Y, Guevara J. 2014. Correspondence amongst the PENO test battery cognitive results and hippocampal lesions in Alzheimer's disease. Adv Aging Res 3:1-13.
51. Sales JM, Resurreccion AV. 2014. Resveratrol in peanuts. Crit Rev Food Sci Nutr 54:734-770.
52. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. 2007. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501-1508.
53. Segovia G, Del Arco A, Garrido P, de Blas M, Mora F. 2008. Environmental enrichment reduces the response to stress of the cholinergic system in the prefrontal cortex during aging. Neurochem Int 52:1198-1203.
54. Segovia G, Porras A, Del Arco A, Mora F. 2001. Glutamatergic neurotransmission in aging: a critical perspective. Mech Ageing Dev 122:1-29.
55. Serrano F, Klann E. 2004. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev 3:431-443.
56. Sesack SR, Grace AA. 2010. Cortico-basal ganglia reward network: Microcircuitry. Neuropsychopharmacology 35:27-47.
57. Sharma M, Gupta YK. 2011. Chronic treatment with trans-resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 71:2498.
58. Shim KS Lubec G., Drebrin 2002. A dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 324:209-212.
59. Shin JA, Lee H, Lim YK, Koh Y, Choi JH, Park EM. 2010. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J Neuroimmunol 227:93-100.
60. Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. 2010. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 30:328-339.
61. Silva-Gomez AB, Rojas D, Juarez I, Flores G. 2003. Decreased dentritic spine density on prefrontal cortical and hippocampal pyramidal neurons in postwearing social isolation rats. Brain Res 983:128-136.
62. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, Jones PB, Stern EA, Bacskai BJ, Hyman BT. 2007. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 171:1304-1311.
63. Sun AY. Wang Q, Simonyi A, Sun GY, Botanical Phenolics and Neurodegeneration. 2011. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: Biomolecular and clinical aspects, 2nd ed. Boca Raton (FL): CRC Press; Chapter 15.
64. Thierry AM, Gioanni Y, Dégénétais E, Glowinski J. 2000. Hippocampo-prefrontal cortex pathway: Anatomical and electrophysiological characteristics. Hippocampus 10:411-419.
65. Uylings HB, de Brabander JM. 2002. Neuronal changes in normal human aging and Alzheimer's disease. Brain Cogn 49:268-276.
66. Vega E, Gomez-Villalobos MJ, Flores G. 2004. Alteration in dendritic morphology of pyramidal neurons from the prefrontal cortex of rats with renovascular hypertension. Brain Res 1021:112-118.
67. Vos PE, Wolterink G, van Ree JM. 1995. The behavioral effects of habituation and challenge with apomorphine after 6-OHDA lesioning of the nucleus accumbens in rats. Eur Neuropsychopharmacol 5:471-476.
68. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM. 2006. Moderate consumption of Cabernet Sauvignon attenuates A-beta neuropathology in a mouse model of Alzheimer's disease. FASEB J 20:2313-2320.
69. Watson JB, Khorasani H, Persson A, Huang KP, Huang FL, O'Dell TJ. 2002. Age-related deficits in long-term potentiation are insensitive to hydrogen peroxide: Coincidence with enhanced autophosphorylation of Ca2+/calmodulin-dependent protein kinase II. J Neurosci Res 70:298-308.
70. Zähringer H, Thevelein JM, Nwaka S. 2000. Induction of neutral trehalase Nth1 by heat and osmotic stress is controlled by STRE elements and Msn2/Msn4 transcription factors: Variations of PKA effect during stress and growth. Mol Microbiol 35:397-406.